New multifunctional ligands for potential use in the design therapeutic or diagnostic radiopharmaceutical imaging agents
A class of diagnostic and therapeutic compounds are derived from phosphinimines that include ligands containing either a single phosphinimine functionality or both a phosphinimine group and a phosphine or arsine group, or an aminato group, or a second phosphinimine moiety. These phosphinimine ligands are complexed to early transition metal radionuclides (e.g., {sup 99m}Tc or {sup 186}Re/{sup 188}Re) or late transition metals (e.g., {sup 105}Rh or {sup 109}Pd). The complexes with these metals {sup 186}Re/{sup 188}Re, {sup 99m}Tc and {sup 109}Pd exhibit a high in vitro and high in vivo stability. The complexes are formed in high yields and can be neutral or charged. These ligands can also be used to form stable compounds with paramagnetic transition metals (e.g., Fe and Mn) for potential use as MRI contrast agents. Applications for the use of ligands and making the ligands are also disclosed.
- Research Organization:
- Univ. of Missouri, Columbia, MO (United States)
- DOE Contract Number:
- FG02-89ER60875
- Assignee:
- Univ. of Missouri, Columbia, MO (United States)
- Patent Number(s):
- US 5,601,800/A/
- Application Number:
- PAN: 8-211,905
- OSTI ID:
- 441867
- Resource Relation:
- Other Information: PBD: 11 Feb 1997
- Country of Publication:
- United States
- Language:
- English
Similar Records
New [sup 99m]Tc, [sup 186]Re, and [sup 109]Pd complexes of SN and PN ligand systems
Rhenium(V) oxo complexes in chemistry and nuclear medicine